| Molecular formula | C47H58N12O6 |
|---|
| Molecular weight | 887 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 6918297 |
|---|
Examorelin is a synthetic peptide studied in laboratory settings rather than an approved therapeutic. Anyone encountering the name should understand it has no approved medical use at this time.
What Examorelin Is
Examinorelin (PubChem CID 6918297) is a synthetic peptide with the molecular formula C47H58N12O6 and a molecular weight of approximately 887. It has no dailymed drug label, no approved indication, and no marketed brand name. Its regulatory status is unapproved and it exists only as a research compound.
Trial Footprint
Public clinical trial registries currently list no registered studies for examorelin. Without registered trials, there is no available information on study design, patient population, or outcomes for this compound.
FAQ
No. Examorelin is an unapproved, investigational peptide with no FDA-approved label, indication, or brand name. It exists only in a research context.
Examorelin is a synthetic peptide with the molecular formula C47H58N12O6 and a molecular weight of about 887. Its identity is catalogued under PubChem CID 6918297.
As of the latest data pull, no clinical trials for examorelin are registered in public trial databases. This means no phase, design, or outcome information is currently available.
Because examorelin has no approved label or completed trial record, there is no established or approved use to describe. It remains a subject of early research interest only.
No adverse event reports or safety monitoring data are currently available for examorelin. Its unapproved and minimally studied status means safety in humans has not been established.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-08-03